Research programme: CD26 antigen inhibitors - America Stem Cell/DARA Biosciences

Drug Profile

Research programme: CD26 antigen inhibitors - America Stem Cell/DARA Biosciences

Latest Information Update: 31 Aug 2012

Price : $50

At a glance

  • Originator America Stem Cell; DARA Biosciences
  • Developer America Stem Cell; DARA BioSciences
  • Class Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological disorders

Most Recent Events

  • 31 Aug 2012 Discontinued for Haematological disorders in USA (unspecified route)
  • 11 Aug 2009 Early research in Haematological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top